Table 1 Clinical characteristics of T2DM patients and healthy control.

From: Increased monocytic myeloid-derived suppressor cells in type 2 diabetes correlate with hyperglycemic and was a risk factor of infection and tumor occurrence

Characteristics†

All T2DM patients (n = 77)

GGC (n = 17)

PGC (n = 60)

Healthy Control (n = 102)

Normal value‡

FPG (mmol/L)

7.24 (5.76, 9.59)

5.26 (4.73, 5.88)

8.23* (6.35, 10.03)

5.17 (4.91, 5.37)

3.90–6.1

HbA1c (%)

8.70 (7.30, 10.30)

6.70 (6.40, 7.25)

9.55* (7.88, 10.88)

5.40 (5.20, 5.50)

4.0–6.0

Age (Years)

54.00 (48.00, 61.00)

49.00 (42.50, 58.00)

55.00* (50.25, 61.00)

53.00 (49, 57.5)

–

Gender, Male (%)

48.05% (n = 37)

47.06% (n = 8)

48.33% (n = 29)

46.07% (n = 47))

–

BMI

24.25 (22.64, 26.13)

24.13 (23.23, 25.24)

24.43 (22.50, 26.19)

19.65 (18.47, 20.31)

18.5–22.9

T2DM duration (Years)

9.50 (4.00, 10.75)

9.00 (1.50, 10.00)

10.00 (5.00, 12.00)

–

–

TG (mmol/L)

1.61 (1.06, 2.52)

1.51 (0.99, 2.03)

1.64 (1.19, 2.72)

1.24 (0.99, 1.61)

0.56–1.70

TC (mmol/L)

4.64 (3.75, 5.46)

4.35 (3.63, 5.13)

4.66 (3.84, 5.47)

4.90 (4.39, 5.69)

2.86–5.98

HDL-C (mmol/L)

0.99 (0.82, 1.18)

0.98 (0.80, 1.10)

1.00 (0.82, 1.21)

1.44 (1.22, 1.59)

1.04 ~ 1.55

LDL-C (mmol/L)

2.85 (2.35, 3.37)

2.78 (2.27, 3.22)

2.86 (2.33, 3.49)

2.59 (2.47, 3.05)

0 ~ 3.37

WBC(109/L)

6.41 (5.76, 7.47)

6.32 (5.45, 8.57)

6.52 (5.86, 7.38)

5.67 (4.89, 7.10)

3.50–9.50

Lymphocyte (109/L)

1.96 (1.56, 2.21)

2.14 (1.92, 2.51)

1.86 (1.49, 2.13)

1.93 (1.50, 2.50)

1.10–3.20

Neutrophil (109/L)

3.81 (3.06, 4.93)

3.55 (3.06, 5.26)

3.90 (3.01, 4.92)

3.04 (2.46, 4.11)

1.80–6.30

Monocyte (109/L)

0.45 (0.37, 0.57)

0.49 (0.35, 0.55)

0.44 (0.37, 0.59)

0.39 (0.30, 0.50)

0.1–0.60

  1. †The Data are expressed as median (interquartile range).
  2. ‡The normal reference values were reported by the Clinical Examination Centre of the hospital.
  3. *Compared with the GGC patient group (P < 0.05, assessed by non-parametric testing, Kolmogorov–Smirnov test).
  4. GGC T2DM patients with good glycemic control (FPG ≤ 7.2 mmol/L and HbA1c ≤ 7.0%); PGC T2DM patients with poor glycemic control (FPG > 7.2 mmol/L or HbA1c > 7.0%).
Back to article page